Department of Pathology, Yale School of Medicine, 200 South Frontage Road, EP2-631, New Haven, CT 06510, USA.
Hematol Oncol Clin North Am. 2023 Jun;37(3):463-473. doi: 10.1016/j.hoc.2023.02.001. Epub 2023 Mar 22.
Advances in the treatment of non-small cell lung carcinoma have resulted in improved histologic classification and the implementation of molecular testing for predictive biomarkers into the routine diagnostic workflow. Over the past decade, molecular testing has evolved from single-gene assays to high-thoroughput comprehensive next-generation sequencing. Economic barriers, suboptimal turnaround time to obtain the results, and limited tissue available for molecular assays resulted in adoption of liquid biopsies (ctDNA) into clinical practice. Multiplex immunohistochemical/immunofluorescence assays evaluating tumor microenvironment together with the AI approaches are anticipated to translate from research into clinical care.
非小细胞肺癌的治疗进展导致了组织学分类的改进，并将预测生物标志物的分子检测纳入常规诊断工作流程。在过去的十年中，分子检测已经从单基因检测发展到高通量的全面下一代测序。经济障碍、获得结果的周转时间不理想以及用于分子检测的组织有限，导致液体活检（ctDNA）被纳入临床实践。评估肿瘤微环境的多重免疫组化/免疫荧光检测与人工智能方法相结合，有望从研究转化为临床护理。
